PathoQuest's proprietary next-generation sequencing (NGS) based testing approach delivers actionable reports to clinicians, biologists, and biopharmaceutical quality assurance managers/production managers. The company's technology combines sample preparation technology and cloud-based bioinformatics, which is applicable to several types of samples with a proprietary pathogen genome sequence database and automated analysis pipeline. PathoQuest's Viral Safety testing service, directed towards biopharmaceutical companies, is the company's first commercial application of its testing approach and has quickly established a revenue stream for the company from several major biopharma companies. PathoQuest helps biopharmaceutical developers and manufacturers get their therapies to market with their leading expertise in GMP NGS-based biosafety testing and characterization services. The company's genomic approach of Next Generation Sequencing (NGS) can solve many of the challenges that are faced by developers and manufacturers, such as lower volume requirements and incompatibility with cell-based assays. PathoQuest has a global footprint, with operations in Europe (Paris) and North America (Wayne, PA), and has provided NGS biosafety testing services to over 100 of the top biopharmaceutical companies globally.